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Summary and Implications 
       The recent emergence of the pandemic H1N1 viruses 
and their being labeled as ‘swine flu’ has had several 
detrimental effects on the pork industry. Novel H1N1 strains 
have been recently detected in swine populations in the 
United States and in other parts of the world. While the 
public health significance of these findings is unknown, it is 
important to determine whether existing vaccines or 
exposure to previously circulating strains of swine influenza 
will protect pigs against the novel H1N1. Using a partial 
two-way cross-hemagglutination inhibition (HI) assay, we 
have determined a swine H1N1 strain present in a 
commercial vaccine cross-reacted with antiserum specific to 
the novel H1N1. We have also shown that a field serum 
sample with a HI high titer to a ’99 H1N1 strain cross-
reacted strongly with the novel H1N1. Anti-sera which were 
specific to the non-pandemic H1N1 strains also cross-
reacted with the novel H1N1. Therefore, we conclude that 
current vaccines and circulating non-pandemic H1N1 field 
strains will provide at least partial protection against the 
novel H1N1 virus in pigs. 
 
Introduction 
       Since April 2009, pandemic H1N1 infections have 
spread rapidly in human populations all over the world 
causing considerable morbidity and mortality. Recently a 
state of national emergency was declared as the number of 
human deaths due to the H1N1 strain exceeded one 
thousand. While it is not known exactly when or where the 
genetic re-assortment that led to the emergence of the recent 
pandemic H1N1 influenza occurred, it is speculated that it is 
the consequence of a recombination between the North 
American triple reassortant and Eurasian lineages of swine 
influenza virus (SIV). Therefore, the virus has acquired the 
popular name of ‘swine flu’ and unprecedented public 
health significance. 
       While there are no documented cases of swine-to-
human transmission of the novel H1N1, recently reverse-
zoonotic transmissions of the novel H1N1 from human-to-
swine and poultry have been recorded. Clinical infections of 
the novel H1N1 in swine are indistinguishable from 
infections with other swine influenza strains, in terms of 
morbidity or mortality. Therefore, the virus may not pose a 
more severe threat to swine health or production when 
compared to commonly circulating swine influenza viruses. 
However, detailed experimental characterization of H1N1 
pathogenesis is lacking. Surveillance for the novel H1N1 in 
swine and domestic birds is purely voluntary in the United 
States and does not require extermination in the event of 
discovery. However, due to the public health significance of 
the virus, it is important to evaluate whether existing 
vaccines or immunity to previously circulating SIV strains 
protect swine against the novel H1N1. This information is 
also important in making decisions regarding the need for a 
novel H1N1 vaccine for swine. Hemagglutination inhibition 
test (HI) titers have been known to correlate well with 
protection against influenza. In this study, we have 
determined the cross-reactivity of the novel H1N1 against 
selected vaccine and field strains of SIV as a first step in 
addressing the above question. 
 
Materials and Methods 
Virus strains and anti-sera: We obtained the novel H1N1 
strain A/CA/04/2009 from the influenza branch, CDC. 
Specific sera against the novel H1N1 strains A/CA/04/2009 
and A/ Mexico/4108/2009 were generated by infection of 
two pigs each. The sera samples were checked by a Multi-
species Enzyme Linked Immunosorbent Assay (ELISA) 
which is non-subtype specific (Idexx Inc.) (Table2).  
          Flu Sure™ XP is a commercial swine influenza 
vaccine marketed by Pfizer Animal Health, Inc. 
(Kalamazoo, MI). It contains a human-like H1N2 virus 
(Pfizer 031 – 95% identical to A/Hu/NY/294/2003), a H1N1 
virus isolated in 1999 (Pfizer 161 – 95% identical to 
A/SW/IN/2000) and a cluster IV H3N2 virus. The human-
like H1N1 and the reassortant H1N1 vaccine virus strains 
were provided by Pfizer Inc. for routine testing of client 
samples in the ISU-VDL serology section. Antisera specific 
to the Pfizer human-like H1N1 and the reassortant H1N1 
vaccine strains were also provided by Pfizer Inc. A classical 
H1N1 virus isolated in 1973 and a H1N1 strain (35233-99) 
isolated in 1999 were available to us. A field sample with a 
known high titer to the 35233-99 strain was used to 
determine cross-reactivity to the novel H1N1. Swine sera 
samples generated from a previously published study where 
eight groups of four pigs each were infected with swine 
influenza viruses, which are representative of the three 
currently circulating swine influenza virus subtypes H1N1, 
H1N2 and H3N2 (Table 2), were provided by Dr. Bruce 
Janke, ISU-VDL. 
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Culture of the novel H1N1 virus strain A/CA/04/2009:  
MDCK cells were cultured for 48-72 hrs until an 
approximate ~80% monolayer was achieved.  Monolayered 
cells were inoculated with A/CA/04/2009 virus.  Cells 
incubated for 2 hours in a 5%, 37°C, CO2 incubator.  The 
virus was removed from the cells and new medium with 
10% fetal bovine serum (FBS) was added to the cells.  Cells 
were incubated for 36-48 hours until 25-75 % cytopathic 
effect (CPE) was observed.  Thereafter, flasks were frozen 
to below -70°C and thawed to release cell-associated virus. 
Cultures were centrifuged and tested for HA units before 
aliquoting and storing virus for future use. 
Hemagglutination inhibition assay: 50 µl of each serum 
sample and high positive, low positive and negative controls 
were added to a deep well plate.  Samples were pretreated 
with heat-inactivation, 20% Kaolin, and 0.4% rooster red 
blood cells (RBC) before transferring to dilution plate. 
Serial two-fold dilutions were performed on samples in a 
dilution plate with one row serving as a negative control.  8 
HA units of the virus were added to the diluted serum on a 
separate micro-titer plate and incubated for 40 minutes.  
0.4% rooster RBC solution was added and incubated for 60 
minutes.  Plates were assessed for the formation of a button 
or crenation.   
 
Results and Discussion 
       Pigs infected with the A/ Mexico/4108/2009 novel 
H1N1 strain appeared to mount lower homologous 
hemagglutinating antibody responses compared to pigs 
infected with the A/CA/04/2009 strain. Both novel H1N1 
strains cross-reacted with the 35233-99 Iowa '99 H1N1 
strain, while A/CA/04/2009 cross-reacted with the 1973 
classical H1N1 strain and the A/ Mexico/4108/2009 strain 
did not. However, this difference could be attributed to the 
low homologous HI titers for this virus.  
      Importantly, the A/Mexico/4108/2009 and 
A/CA/04/2009 specific antisera cross-reacted with the 
Pfizer re-assortant H1N1 vaccine strain although the titers 
were not high, indicating that currently available vaccine 
would confer a degree of protection against the novel H1N1. 
In confirmation, antisera raised against the two vaccine 
virus strains described in Table 1, cross-reacted with 
A/CA/04/2009. However, negligible there was negligible 
cross-reactivity between the human-like H1N1 vaccine 
strain and A/CA/04/2009 (Table 1). 
         More interestingly, a field serum sample which was 
found to have high HI titers to the 35233-99 Iowa '99 H1N1 
strain reacted equally as strong with the novel H1N1 strains, 
indicating that a pre-existing and robust protection against 
the novel H1N1 strains is highly likely in field conditions. 
However, this field serum sample is not very well 
characterized in terms of the other viruses the pig might 
have been exposed to.   
         Similarly, A/CA/04/2009 showed varying levels of HI 
activity with pigs experimentally infected with the classical 
H1N1, re-assortant H1N1, and two clusters of H1N2 (Table 
2). As expected, A/CA/04/2009 showed no cross-reactivity 
with serum from pigs experimentally infected with three 
different H3N2 clusters. 
        Therefore, we speculate that existing SIV vaccines will 
confer a degree of protection against the novel H1N1 and 
that currently circulating SIV strains can serve the same 
function. However, as the novel H1N1 has been recently 
transmitted from humans to swine in different parts of the 
world, it is important to scientifically assess whether such 
existing protection can provide herd-level immunity. It is 
also important to recognize that sub-optimal levels of 
protection in a population could result in negative selection 
pressure which may force the virus to evolve into more 
pathogenic forms, especially given the public health 
significance of the novel H1N1.   More systematic and 
thorough studies are required to address this critical 
question. 
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Table 1. Antigenic cross-reactivity of the novel H1N1 with vaccine strains. 
 
Serum/ Virus Novel  
H1N1 
(A/CA/04
/2009) * 
35233-
99  
Iowa 
'99 
H1N1* 
Pfizer 
Re-
assortant 
H1N1* 
Pfizer 
H031 
(Human-
like 
H1N2)* 
1973 
classical 
H1N1  
(-ISU-
VDL)* 
A/CA/04/2009 Pig 574 160 160 40 ≤ 10 20 
A/CA/04/2009 Pig 575 320 80 40 ≤ 10 40 
A/ Mexico/4108/09 Pig 603 80 20 20 ≤ 10 ≤ 10 
A/ Mexico/4108/09 Pig 604 40 40 20 ≤ 10 ≤ 10 
Field sample with high  H1N1 titer 640 640    
Pfizer re-assortant H1N1 Positive 
control 
40 640 640 ≤ 10  
Pfizer H031 Human-like H1N2 20   640  
Negative  controls ≤ 10 ≤ 10 ≤ 10 ≤ 10 ≤ 10 
      
 * Mean reciprocal HI titer at 8 HA units of each virus 
 
 
Table 2. Cross- reactivity of the novel H1N1 virus to previously circulating SIV strains.  
 
Anti-sera Mean reciprocal HI 
titer against H1N1 
virus A/CA/04/2009  
+,$ 
Mean SIV titer 
*,$ 
cH1N1(A/Swine/IA/40776/92) 33 0.09 
tH1N1A(A/Swine/H02NJ56371/02 +H3N2) 40 0.2 
tH1N1B(A/Swine/IA/35233/99) ≤ 10 0.32 
H1N2A(A/Swine/Wisconsin/R33f/01) 42.5 0.15 
H1N2B(A/Swine/IA/35233/99) 13.33 0.18 
H3N2C1(A/Swine/Texas/4199-2/98) ≤ 10 0.1 
H3N2C2(A/Swine/Texas/4199-2/98) ≤ 10 0.33 
H3N2C3(A/Swine/Texas/00036/02) ≤ 10 0.25 
Pandemic  H1N1  (A/CA/04/2009) 135 0.11 
Negative control ≤ 10 0.92 
   
* -samples with S: N ratios above 0.5 are considered negative 
+ mean reciprocal HI titer with 8 HA units of each virus 
$ 
 mean values for four pigs in each group 
 
 
